Safety and tolerability of RJx-01 to maintain muscle integrity in patients following hospitalisation with an acute exacerbation of COPD (MINT-COPD): protocol for a phase IIa randomised double-blind placebo-controlled trial

Introduction Chronic Obstructive Pulmonary Disease (COPD) is one of the leading causes of global disability and disability-adjusted life years. One of the key systemic features of COPD is impaired skeletal muscle mass and function, termed sarcopenia. The recognition of skeletal muscle dysfunction as a treatable trait in COPD opens a therapeutic avenue for pharmacological development, with the aim of improving physical function and reducing healthcare utilisation. A novel combination drug, RJx-01, was identified as a candidate therapy for sarcopenia based on preclinical evidence. The primary ai

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.